. Author manuscript; available in PMC: 2022 May 1.

Published in final edited form as: Biochem Pharmacol. 2020 Nov 6;187:114321. doi: 10.1016/j.bcp.2020.114321

Table 1.

Protective effects of adenosine kinase inhibition in experimental model systems

Organ Class	Experimental Model/Endpoint
Central Nervous System	Epilepsy – focal and generalized seizures
	Pain – acute, chronic inflammatory and neuropathic
	Traumatic Brain Injury
	Neurotoxicity/neurodegeneration
	Ischemia
	Diabetic retinopathy
	Substance Abuse/drug withdrawal and dependence
	Psychiatric/schizophrenia
	Audition
	Sleep
Cardiovascular	Atherosclerosis
	Hypertension
	Myocardial Infarction
	Ischemia/reperfusion
	Cardiac remodeling
Renal	Acute kidney injury
	Chemotherapy induced nephrotoxicity
	Diabetic renal injury
Immunological/Oncological	Inflammation/ acute and chronic
	colitis
	Host defense
	B-cell proliferation
	T-cell production
	Melanoma

ADK inhibitors have been investigated across a diverse array of model systems targeting central nervous system, cardiovascular, renal and immuno-oncological disorders. Data derived from [2,6–8,34,48] and PubMed using “adenosine kinase inhibitor” as a search term.